Gynecologic Oncology Clinical Research Group

MULTIDISCIPLINARY APPROACH TO THE DISEASE

The management of gynecological cancer is complex and involves multiple specializations. Every case is discussed in a multidisciplinary session in the light of the most up-to date scientific evidence. The objective is to conduce the patient through the complex and challenging diagnostic and therapeutic path, offering the best options for her case all along her disease history.

IMMUNOTHERAPY IS THE NEW FRONTIER

Immunotherapy is one of the most important achievement in last years against cancer. However, there are still many challenges that must be overcome; in particular, in gynecolagical cancer many drugs are still in phase of development.

Treatment with anti-PD1 and antiPD-L1 antibodies represents a large field of research in our center, for example in endometrial and cervical cancer with microsatellite instability (MSI-H), which seem to be particularly sensitive to this kind of therapy.

Combination treatment with immunotherapeutic agents and target therapies such as PARP-inhibitor are under investigation also in ovarian cancer.

REAL WORD EVIDENCE STUDIES

To explore the outcome of gynecological tumors in real world practice and to investigate molecular and clinical characteristics impacting on it, we are running observational, large, disease-specific studies on ovarian cancers. These analyses will give the opportunity to improve clinical practice and to generate hypotesis for new clinical researches. Moreover these kind of research allows to better understand the long term effects of our treatments, both on the side of efficacy and of their possible toxicity.